Catherine Shaffer

Adults with BRAF-mutated glioma have higher-grade tumors and decreased survival compared to children but can still benefit from targeted therapies.

Economics and market incentives have ingrained maximum-tolerated dosing paradigms in cancer drug trials, but the FDA and patient advocates are pushing for change.

The San Francisco-based company will use the funds to commercialize the ArteraAI Prostate Cancer test in the US and internationally, and develop similar tests for other cancers.

The company wants to market a test based on studies showing that blood vessel tortuosity can predict therapy response and survival across cancers.

Investigators hope to overcome obstacles to immunotherapy response in solid tumors with a combination approach targeting novel neoantigens on the tumor surface.

The firm sees significant market opportunity for its AXL inhibitor bemcentinib combined with Keytruda in advanced NSCLC patients with SKT11 mutations.

The program will foster and fund innovative, high-risk research with the goal of elucidating the biological underpinnings of metastasis in all types of cancer.

The firm looks forward to launching new trials in 2023 and building out its breast and lung cancer treatment portfolios.

Even though the company's COVID-19 products are declining in sales, Roche's personalized oncology products, Tecentriq and Perjeta, performed well during the quarter and year.

Researchers used immune-related gene expression signatures to zero in on B-cell involvement missed by TIL assessment in HER2-positive breast cancer patients.